-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Buys $38,700.00 in Stock
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Buys $38,700.00 in Stock
Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) CEO Snehal Patel bought 2,000 shares of Greenwich LifeSciences stock in a transaction on Friday, January 27th. The stock was purchased at an average price of $19.35 per share, with a total value of $38,700.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,734,886 shares of the company's stock, valued at approximately $52,920,044.10. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Snehal Patel also recently made the following trade(s):
Get Greenwich LifeSciences alerts:- On Friday, January 20th, Snehal Patel acquired 1,500 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $17.37 per share, for a total transaction of $26,055.00.
- On Friday, January 6th, Snehal Patel acquired 1,500 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $15.18 per share, with a total value of $22,770.00.
- On Friday, December 16th, Snehal Patel bought 1,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $13.01 per share, with a total value of $13,010.00.
- On Friday, December 9th, Snehal Patel purchased 2,000 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $13.11 per share, for a total transaction of $26,220.00.
- On Friday, December 2nd, Snehal Patel acquired 1,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $13.84 per share, with a total value of $13,840.00.
- On Wednesday, November 2nd, Snehal Patel bought 2,000 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $8.79 per share, for a total transaction of $17,580.00.
Greenwich LifeSciences Stock Performance
Shares of GLSI stock opened at $19.44 on Tuesday. Greenwich LifeSciences, Inc. has a fifty-two week low of $6.82 and a fifty-two week high of $26.27. The stock's 50-day simple moving average is $14.92 and its 200-day simple moving average is $11.34.
Greenwich LifeSciences (NASDAQ:GLSI – Get Rating) last released its earnings results on Monday, November 14th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.01. Equities analysts anticipate that Greenwich LifeSciences, Inc. will post -0.57 earnings per share for the current fiscal year.Institutional Investors Weigh In On Greenwich LifeSciences
Large investors have recently made changes to their positions in the stock. Bank of America Corp DE raised its stake in Greenwich LifeSciences by 100.2% in the 1st quarter. Bank of America Corp DE now owns 6,213 shares of the company's stock worth $122,000 after acquiring an additional 3,110 shares during the last quarter. Walleye Capital LLC acquired a new position in shares of Greenwich LifeSciences in the second quarter valued at about $90,000. Goldman Sachs Group Inc. purchased a new position in shares of Greenwich LifeSciences in the second quarter worth about $104,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Greenwich LifeSciences during the second quarter worth about $130,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Greenwich LifeSciences during the second quarter worth about $150,000. 6.18% of the stock is owned by hedge funds and other institutional investors.
Greenwich LifeSciences Company Profile
(Get Rating)
Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Featured Articles
- Get a free copy of the StockNews.com research report on Greenwich LifeSciences (GLSI)
- Lucid Group's Buyout Rumors Continue
- Is Zimmer Biomet a Buy Ahead of Earnings?
- Tesla's Recovery Gains Momentum
- Is It Worth Toying Around With Hasbro's Drop?
- Trading Volume on Fisker Is Electric! Uptrend On?
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) CEO Snehal Patel bought 2,000 shares of Greenwich LifeSciences stock in a transaction on Friday, January 27th. The stock was purchased at an average price of $19.35 per share, with a total value of $38,700.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,734,886 shares of the company's stock, valued at approximately $52,920,044.10. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
格林威治生命科技有限公司(納斯達克:GLSI-獲取評級)首席執行官斯內哈爾·帕特爾在 1 月 27 日星期五的交易中購買了 2,000 股格林威治生命科技股票。該股票以每股 19.35 美元的平均價格購買,總價值為 38,700.00 美元。收購完成後,首席執行官現直接擁有該公司股份的 2,734,886 股股份,價值約為 52,920,044.10 美元。購買在向 SEC 提交的文件中披露,可以通過以下方式訪問 證券交易所網站。
Snehal Patel also recently made the following trade(s):
斯內哈爾·帕特爾最近還進行了以下交易:
- On Friday, January 20th, Snehal Patel acquired 1,500 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $17.37 per share, for a total transaction of $26,055.00.
- On Friday, January 6th, Snehal Patel acquired 1,500 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $15.18 per share, with a total value of $22,770.00.
- On Friday, December 16th, Snehal Patel bought 1,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $13.01 per share, with a total value of $13,010.00.
- On Friday, December 9th, Snehal Patel purchased 2,000 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $13.11 per share, for a total transaction of $26,220.00.
- On Friday, December 2nd, Snehal Patel acquired 1,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $13.84 per share, with a total value of $13,840.00.
- On Wednesday, November 2nd, Snehal Patel bought 2,000 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $8.79 per share, for a total transaction of $17,580.00.
- 上週五, 1 月 20 日, 斯內哈爾·帕特爾收購了 1,500 股格林威治生命科技股票.該股票的購買價格為每股 17.37 美元,總交易額為 26,055.00 美元。
- 1 月 6 日星期五,斯內哈爾·帕特爾收購了 1,500 股格林威治生命科技股票。這些股份以每股 15.18 美元的平均價格購買,總價值為 22,770.00 美元。
- 上週五, 12 月 16 日, 斯內哈爾·帕特爾買了 1,000 股格林威治生命科技股票.該股票以每股 13.01 美元的平均價格購買,總價值為 13,010.00 美元。
- 上週五, 12 月 9 日, 斯內哈爾·帕特爾購買 2,000 格林威治生命科技股票的股票.這些股份以每股 13.11 美元的平均成本收購,總交易額為 26,220.00 美元。
- 12 月 2 日星期五,斯內哈爾·帕特爾收購了 1,000 股格林威治生命科技股票。該股票以每股 13.84 美元的平均成本收購,總價值為 13,840.00 美元。
- 上週三, 11 月 2 日, 斯內哈爾·帕特爾買 2,000 格林威治生命科技股票的股票.這些股份以每股 8.79 美元的平均成本收購,總交易額為 17,580.00 美元。
Greenwich LifeSciences Stock Performance
格林威治生命股票表現
Shares of GLSI stock opened at $19.44 on Tuesday. Greenwich LifeSciences, Inc. has a fifty-two week low of $6.82 and a fifty-two week high of $26.27. The stock's 50-day simple moving average is $14.92 and its 200-day simple moving average is $11.34.
GLSI 股票的股份週二開盤價為 19.44 美元。格林威治生命科技有限公司的五十兩周低點為 6.82 美元,五十二周新高為 26.27 美元。該股票的 50 天簡單移動平均線為 14.92 美元,其 200 天簡單移動平均線為 11.34 美元。
Institutional Investors Weigh In On Greenwich LifeSciences
機構投資者權衡格林威治的生命
Large investors have recently made changes to their positions in the stock. Bank of America Corp DE raised its stake in Greenwich LifeSciences by 100.2% in the 1st quarter. Bank of America Corp DE now owns 6,213 shares of the company's stock worth $122,000 after acquiring an additional 3,110 shares during the last quarter. Walleye Capital LLC acquired a new position in shares of Greenwich LifeSciences in the second quarter valued at about $90,000. Goldman Sachs Group Inc. purchased a new position in shares of Greenwich LifeSciences in the second quarter worth about $104,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Greenwich LifeSciences during the second quarter worth about $130,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Greenwich LifeSciences during the second quarter worth about $150,000. 6.18% of the stock is owned by hedge funds and other institutional investors.
大型投資者最近更改了他們在股票中的頭寸。美國銀行公司 DE 在第一季度提高了 100.2% 在格林威治生命的股份。美國銀行股份有限公司在上一季度額外購入 3,110 股股份後,現在擁有該公司股票的 6,213 股,價值 122,000 美元。華勒眼資本有限責任公司在第二季度收購了格林威治生命科技股份的新職位,價值約為 90,000 美元。高盛集團在第二季度購買了格林威治生命科技股份的新頭寸,價值約為 104,000 美元。立體派系統策略有限責任公司在第二季度收購了格林威治生命科技股份的新股份,價值約 130,000 美元。最後,城堡顧問有限責任公司在第二季度收購了格林威治 LifesCences 股份的新股份,價值約為 150,000 美元。6.18% 的股票由對沖基金和其他機構投資者擁有。
Greenwich LifeSciences Company Profile
格林威治生命科技公司簡介
(Get Rating)
(取得評分)
Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
格林威治 Lifesciences, Inc. 是一家臨床階段生物製藥公司,致力於開發針對乳腺癌和其他 Her2/NEI 表達癌症的新型癌症免疫療法。其主要候選產品是 GP2,這是一種免疫療法,該療法已完成 IIb 期臨床試驗,以防止先前接受過手術的患者乳腺癌復發。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Greenwich LifeSciences (GLSI)
- Lucid Group's Buyout Rumors Continue
- Is Zimmer Biomet a Buy Ahead of Earnings?
- Tesla's Recovery Gains Momentum
- Is It Worth Toying Around With Hasbro's Drop?
- Trading Volume on Fisker Is Electric! Uptrend On?
- 獲取有關格林威治生命研究報告(GLSI)的免費副本
- 清醒集團的收購謠言繼續
- 齊默生物特是收益提前購買的嗎?
- 特斯拉的恢復增長勢頭
- 孩之寶的水滴值得玩弄嗎?
- 菲斯克的交易量是電動的!上升趨勢在?
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接收格林威治生命日報的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收格林威治 Lifesciences 和相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧